Perrigo ($PRGO) has further solidified its position in topical dermatology drugs, one of the areas in which prices have been escalating of late.
"We continue to market the only generic foam products in the U.S. and expect to launch two additional products--generic versions of Luxiq (betamethasone valerate) Foam and Olux-E (clobetasol propionate) Foam 0.05%--during this fiscal year, which is a testament to the challenges of this dosage form and success of our partnership with Cobrek," Perrigo CEO Joseph C. Papa said.
Last person at the Stiefel office please turn off the lights